Agenda*

Friday, October 25

1:00–2:00 pm

Registration and Refreshments with Exhibitors

2:00–2:10 pm

Welcome and Program Overview

Phillip Koo, MD, Banner MD Anderson Cancer Center

2:10–2:30 pm

Reintroducing Therapeutics: Nuclear Medicine Physician Leading Patient Care Team

Dan Pryma, MD, University of Pennsylvania

2:30–3:30 pm

Establishing Your Practice in Systemic Radiation Therapy in Theranostics Practice / 
The Role of Technologists in Theranostics Practice

Sandy McEwan, MD, Ipsen Radiopharmaceuticals

3:30–3:40 pm

Question and Answer

3:40–4:00 pm

Operationalizing a 177Lu-Dotatate Clinic

Jennifer Kwak, MD, University of Colorado

4:00–4:15 pm

Break

4:15–4:35 pm

Operationalizing Your Practice For 223Ra-Dichloride

Phillip Koo, MD, Banner MD Anderson Cancer Center

4:35–4:55 pm

Operationalizing Your Practice For 177Lu-PSMA Based Therapies

Phillip Kuo, MD, PhD, University of Arizona

4:55–5:40 pm

Primer for the Radiation Safety Officer, from Patient Release to Waste Management

Michael Sheetz, MS, CHP, DABMP, University of Pittsburgh

5:40-5:50 pm

Question and Answer

5:50–7:00 pm

Reception with Exhibitors

Saturday, October 26

7:30–8:30 am

Breakfast with Exhibitors

THERAPEUTICS IN THE ENDOCRINE SYSTEM

8:30–9:15 am

Updates and Controversies of Radioiodine Theranostic in Differentiated Thyroid Cancer

Douglas Van Nostrand, MD, FACP, FACNM, MedStar Washington Hospital Center

9:15–10:00 am

The Role of I-131 MIBG in the Treatment of Neuroendocrine Cancers

Daniel Pryma, MD, University of Pennsylvania

10:00–10:15 am

Question and Answer

10:15-10:45 am       

Coffee Break with Exhibitors

THERAPEUTICS IN THE GASTROINTESTINAL SYSTEM

10:45–11:30 am

Overview of the Treatment Landscape in Neuroendocrine Malignancies

Christopher Lieu, MD, University of Colorado; Jennifer Kwak, MD, University of Colorado

11:30–11:55 am

Optimizing the Use of 177Lu-Dotatate in Clinical Practice and Cases

Jennifer Kwak, MD, University of Colorado

11:55 am–12:20 pm

Co-Managing the Patient with Metastatic Neuroendocrine Disease

Christopher Lieu, MD, University of Colorado

12:20–12:30 pm

Question and Answer

12:30–1:30 pm

Lunch with Exhibitors

THERAPEUTICS IN THE GENITO-URINARY SYSTEM – PROSTATE CANCER

1:30–2:00 pm

Overview of the Treatment Landscape in Castration-Resistant Prostate Cancer

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center

2:00–2:30 pm

The Role of 223Ra-Dichloride

Phillip Koo, MD, Banner MD Anderson Cancer Center

2:30–3:00 pm

Current Status of 177Lu-PSMA Based Therapies and What is Coming Down the Road

Phillip Kuo, MD, PhD, University of Arizona

3:00–3:50 pm

Co-Managing the Patient with Metastatic Castration-Resistant Prostate Cancer

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center; Phillip Koo, MD, Banner MD Anderson Cancer Center; Phillip Kuo, MD, PhD, University of Arizona

3:50–4:00 pm

Question and Answer

4:00–5:00 pm

Reception with Exhibitors

Sunday, October 27

7:30–8:30 am

Breakfast

BILLING AND REGULATORY ISSUES IN THERAPEUTICS

8:30–9:15 am

Coding and Reimbursement in Therapeutics

Denise Merlino, CNMT, CPC, MBA, FSNMMIT, Merlino Health Care Consulting Corp.

9:15–9:45 am

Licensing and regulatory requirements for Targeted Alpha Therapies

Shaemus Gleason, Bayer HealthCare Pharmaceuticals Inc.

9:45–10:00 am

Question and Answer

10:00–10:15 am

Break

10:15–11:00 am

Overview of the Meeting and Roadmap to the Future of Radionuclide Therapy

Phillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania

11:00–11:30 am

Frequently Asked Questions in Radionuclide Therapy

11:30–11:45 am

Closing Remarks

Phillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania

11:45 am

Conference Adjourns